Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Vicore Pharma AB logo — company profile

Vicore Pharma AB

Founded 2009 Sweden Sweden 41 employees Post-IPO Equity Total: $501.50M Biopharma, Biotechnology +1

General Information

Company Name Vicore Pharma AB
Founded Year 2009
Location Sweden Sweden
Employees 41
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Vicore Pharma AB. To contact Vicore Pharma AB, visit vicorepharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vicore Pharma AB compare?

A PDF of Vicore Pharma AB and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vicore Pharma AB soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vicore Pharma AB

Vicore Pharma AB is a Swedish biopharmaceutical company founded in 2009 that focuses on developing drugs with disease-modifying potential for respiratory diseases. It is currently advancing Buloxibutid (C21), the first-in-class orally available small molecule angiotensin II type 2 receptor agonist, through phase 2a development for idiopathic pulmonary fibrosis (IPF). In addition, the company is developing Almee™, a digital therapeutic based on cognitive behavioral therapy, to address the psychological impact of living with pulmonary fibrosis, which has received Breakthrough Device Designation from the FDA. Vicore's unique expertise in ATRAG chemistry and biology is enabling the company to expand its pipeline with several new therapies across potential indications. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. Notably, the company recently secured a kr500.00M Post-IPO Equity investment on 09 June 2023, with leading investors including HBM Healthcare Investments, HealthCap, OrbiMed, AP4, Suvretta Capital Management, Swedbank Robur, Third Swedish National Pension Fund, and SEB (Skandinaviska Enskilda Banken). For more information, visit www.vicorepharma.com.

Business keywords: pharmaceutical company, clinical-stage, respiratory diseases, idiopathic pulmonary fibrosis, ATRAG, phase 2a development, digital therapeutic, breakthrough device designation, drug development, orphan drug designation, rare diseases, Nasdaq Stockholm, Astra Zeneca, bioventurehub, innovative medicines

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity kr500.00M 8
HBM Healthcare Investments HealthCap OrbiMed
HBM Healthcare Investments, HealthCap +6
09 Jun 2023
Grant $1.50M 1
LifeArc
LifeArc
03 Jun 2020

Vicore Pharma AB Alternatives & Competitors

View All Alternatives
Vicore Pharma AB vs
Kither Biotech
Kither Biotech Italy

Improving treatment for patients suffering from incurable respiratory diseases

Series B
18 employees
Biopharma, Biotechnology
Compare Vicore Pharma AB vs Kither Biotech
Vicore Pharma AB vs
AnnJi Pharmaceutical Co., Ltd.
AnnJi Pharmaceutical Co., Ltd. Taiwan

Taiwan's Leading New Drug Developer In Dermatology & Neurology

18 employees
Biotechnology, Health Care
Compare Vicore Pharma AB vs AnnJi Pharmaceutical Co., Ltd.
Vicore Pharma AB vs
Avalyn Pharma
Avalyn Pharma United States

Revolutionizing respiratory care with every breath

Series C
58 employees
Biopharma, Biotechnology
Also compare with: Vicore Pharma AB vs Savara Inc. Savara Inc. View all alternatives

FAQ About Vicore Pharma AB

Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally...
Vicore Pharma AB was founded in 2009.
Vicore Pharma AB is headquartered in Sweden.
Vicore Pharma AB operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on pharmaceutical company, clinical-stage, respiratory diseases and idiopathic pulmonary fibrosis.
Vicore Pharma AB has approximately 41 employees.
Vicore Pharma AB has completed 2 funding rounds, raising a total of $501.50M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Vicore Pharma AB include Kither Biotech, AnnJi Pharmaceutical Co., Ltd., Avalyn Pharma, Syntara, Pliant Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vicore Pharma AB and Kither Biotech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vicore Pharma AB, https://bouncewatch.com/company/vicore-pharma-ab, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes